Literature DB >> 14559363

Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease.

Maja Puchades1, Sara Folkesson Hansson, Carol L Nilsson, Niels Andreasen, Kaj Blennow, Pia Davidsson.   

Abstract

By comparing the cerebrospinal fluid (CSF) proteome between Alzheimer's disease (AD) patients and controls, it may be possible to identify proteins that play a role in the disease process and thus to study the pathogenesis of AD. Two-dimensional gel electrophoresis (2-DE), SYPRO Ruby staining and mass spectrometry were used for clinical screening of disease-influenced CSF proteins in AD patients compared to controls. In order to increase the detection of CSF proteins and to improve the separation of protein isoforms in a 2-D gel, micro-narrow range IPG strips were used. The levels of eight proteins and their isoforms, including apolipoprotein A1, apolipoprotein E, apolipoprotein J, beta-trace, retinol-binding protein, kininogen, alpha-1 antitrypsin, cell cycle progression 8 protein, and alpha-1beta glycoprotein were significantly altered in CSF of AD patients compared to controls. Furthermore, we also used liquid-phase IEF, as a prefractionation step, prior to 2-DE for comparison of CSF proteins between individual AD patients and controls. The levels of 37 proteins spots were altered in AD patients. One of the identified proteins, alpha-2-HS glycoprotein, has not previously been linked to AD. Our study shows that several glycoproteins are altered in AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14559363     DOI: 10.1016/j.molbrainres.2003.08.005

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  74 in total

1.  Discovery and verification of osteopontin and Beta-2-microglobulin as promising markers for staging human African trypanosomiasis.

Authors:  Natalia Tiberti; Alexandre Hainard; Veerle Lejon; Xavier Robin; Dieudonné Mumba Ngoyi; Natacha Turck; Enock Matovu; John Enyaru; Joseph Mathu Ndung'u; Alexander Scherl; Loïc Dayon; Jean-Charles Sanchez
Journal:  Mol Cell Proteomics       Date:  2010-08-19       Impact factor: 5.911

2.  Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry.

Authors:  Judith Y M N Engwegen; Helgi H Helgason; Annemieke Cats; Nathan Harris; Johannes M G Bonfrer; Jan H M Schellens; Jos H Beijnen
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

Review 3.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

4.  Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid.

Authors:  Takahisa Kanekiyo; Tadato Ban; Kosuke Aritake; Zhi-Li Huang; Wei-Min Qu; Issay Okazaki; Ikuko Mohri; Shigeo Murayama; Keiichi Ozono; Masako Taniike; Yuji Goto; Yoshihiro Urade
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-02       Impact factor: 11.205

5.  Post-translational modification regulates prostaglandin D2 synthase apoptotic activity: characterization by site-directed mutagenesis.

Authors:  Louis Ragolia; Christopher E Hall; Thomas Palaia
Journal:  Prostaglandins Other Lipid Mediat       Date:  2006-11-07       Impact factor: 3.072

6.  8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease.

Authors:  Leila Choe; Mark D'Ascenzo; Norman R Relkin; Darryl Pappin; Philip Ross; Brian Williamson; Steven Guertin; Patrick Pribil; Kelvin H Lee
Journal:  Proteomics       Date:  2007-10       Impact factor: 3.984

Review 7.  Translational research in central nervous system drug discovery.

Authors:  Orest Hurko; John L Ryan
Journal:  NeuroRx       Date:  2005-10

8.  Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects.

Authors:  Srikanth Ranganathan; Georgina C B Nicholl; Sarah Henry; Fran Lutka; Ramasri Sathanoori; David Lacomis; Robert Bowser
Journal:  Amyotroph Lateral Scler       Date:  2007-08-03

9.  Mass spectrometry-based proteomics and peptidomics for biomarker discovery in neurodegenerative diseases.

Authors:  Xin Wei; Lingjun Li
Journal:  Int J Clin Exp Pathol       Date:  2008-06-20

Review 10.  Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.

Authors:  Simone Lista; Henrik Zetterberg; Bruno Dubois; Kaj Blennow; Harald Hampel
Journal:  J Neurol       Date:  2014-05-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.